Becton, Dickinson and Company (BDX) recently reported the commercialization of the BD FACSJazz Cell Sorting System, a futuristic flow cytometer. This offering renders the isolation and analysis of cells easier for researchers. The sorter requires 20 inches by 20 inches of space and demonstrates solid ability to recognize and isolate chosen cells.
According to the company, the BD FACSJazz Cell Sorting System will support the quick progress in genomic studies in situations where the integrity of the sample is important for next-generation sequencing. The system is able to recognize and isolate either individual or numerous cells and deposit the same in well plates in a speedy and accurate manner. This sorter takes into account comments from clients from a worldwide early access program held in 2011.
This system has novel features that make sorting an easier task. One such feature is the pre-set optimal setting for accurate targeting of cells. The BD FACSJazz Cell Sorting System may be geared to handle 6 colors with 8 parameters. Its container has been judged by the Baker Company to satisfy certain product and human safety standards.
We nonetheless remain cautious about Becton Dickinson due to the lack of major short-term catalysts. The rising demand for safety-needle products (with higher price points and margins) was the primary driver of the company’s past growth, which is not expected to continue, given that the U.S. market is already largely penetrated.
On the positive side, Becton Dickinson’s preeminent global healthcare products franchise is partly insulated from volatile macroeconomic conditions and structural deficiencies elsewhere in the healthcare delivery field.
Becton Dickinson faces a wide range of competitors, including Baxter International (BAX) in certain niches, in each of its three business segments. We are currently Neutral on the stock, supported by a short-term Zacks #3 Rank (Hold).
Read the Full Research Report on BAX
More From Zacks.com
